When given orally to a transgenic mouse model of Alzheimer disease, cyclohexanehexol stereoisomers inhibit aggregation of amyloid β peptide (Aβ) into high-molecular-weight oligomers in the brain and ameliorate several Alzheimer disease–like phenotypes in these mice, including impaired cognition, altered synaptic physiology, cerebral Aβ pathology and accelerated mortality. These therapeutic effects, which occur regardless of whether the compounds are given before or well after the onset of the Alzheimer disease–like phenotype, support the idea that the accumulation of Aβ oligomers has a central role in the pathogenesis of Alzheimer disease.
Subscribe to Journal
Get full journal access for 1 year
only $4.92 per issue
All prices are NET prices.
VAT will be added later in the checkout.
Tax calculation will be finalised during checkout.
Rent or Buy article
Get time limited or full article access on ReadCube.
All prices are NET prices.
NOTE: In the version of this article initially published online, there was an error in Table 1. In the 6-month prophylactic study under Scyllo-cyclohexanehexol, the soluble Aβ40 level should be 105 ± 8 instead of 1,105 ± 8. The error has been corrected for the HTML and print versions of the article.
Selkoe, D.J. Deciphering the genesis and fate of amyloid beta-protein yields novel therapies for Alzheimer disease. J. Clin. Invest. 110, 1375–1381 (2002).
Glabe, C.C. Amyloid accumulation and pathogenesis of Alzheimer's disease: significance of monomeric, oligomeric and fibrillar Aβ. Subcell. Biochem. 38, 167–177 (2005).
McLaurin, J. & Chakrabartty, A. Membrane disruption by Alzheimer beta-amyloid peptides mediated through specific binding to either phospholipids or gangliosides. Implications for neurotoxicity. J. Biol. Chem. 271, 26482–26489 (1996).
McLaurin, J. & Chakrabartty, A. Characterization of the interactions of Alzheimer beta-amyloid peptides with phospholipid membranes. Eur. J. Biochem. 245, 355–363 (1997).
Koppaka, V. & Axelson, P.H. Accelerated accumulation of amyloid beta proteins on oxidatively damaged lipid membranes. Biochemistry 39, 10011–10016 (2000).
Mizuno, T. et al. Cholesterol-dependent generation of a seeding amyloid beta-protein in cell culture. J. Biol. Chem. 274, 15110–15114 (1999).
Choo-Smith, L.P. & Surewicz, W.K. The interaction between Alzheimer amyloid beta(1–40) peptide and ganglioside GM1-containing membranes. FEBS Lett. 402, 95–98 (1997).
Yanagisawa, K. et al. GM1 ganglioside-bound amyloid beta-protein (A beta): a possible form of preamyloid in Alzheimer's disease. Nat. Med. 1, 1062–1066 (1995).
Auton, M. & Bolen, D.W. Predicting the energetics of osmolyte-induced protein folding/unfolding. Proc. Natl. Acad. Sci. USA 102, 15065–15068 (2005).
McLaurin, J., Franklin, T., Chakrabartty, A. & Fraser, P.E. Phosphatidylinositol and inositol involvement in Alzheimer amyloid-beta fibril growth and arrest. J. Mol. Biol. 278, 183–194 (1998).
McLaurin, J., Goloumb, R., Jurewicz, A., Antel, J.P. & Fraser, P.E. Inositol stereoisomers stabilize an oligomeric aggregate of Alzheimer amyloid beta peptide and inhibit Aβ-induced toxicity. J. Biol. Chem. 275, 18495–18502 (2000).
Chishti, M.A. et al. Early-onset amyloid deposition and cognitive deficits in transgenic mice expressing a double mutant form of amyloid precursor protein 695. J. Biol. Chem. 276, 21562–21570 (2001).
Janus, C. et al. Aβ peptide immunization reduces behavioural impairment and plaques in a model of Alzheimer's disease. Nature 408, 979–982 (2000).
Morris, R. Development of a water-maze procedure for studying spatial learning in the rat. J. Neurosci. Methods 11, 47–60 (1984).
Klein, W.L. Aβ toxicity in Alzheimer's disease: globular oligomers (ADDLs) as a new vaccine and drug targets. Neurochem. Int. 41, 345–352 (2002).
Kayed, R. et al. Common structure of soluble amyloid oligomers implies common mechanism of pathogenesis. Science 300, 486–489 (2003).
Spector, R. Myo-inositol transport through the blood-brain barrier. Neurochem. Res. 13, 785–787 (1988).
Uldry, M. et al. Identification of a mammalian H(+)-myo-inositol symporter expressed predominantly in the brain. EMBO J. 20, 4467–4477 (2001).
Uldry, M. & Thorens, B. The SLC2 family of facilitated hexose and polyol transporters. Pflugers Arch. 447, 480–489 (2004).
Shetty, H.U. & Hollway, H.W. Assay of myo-inositol in cerebrospinal fluid and plasma by chemical ionization mass spectrometry of the hexaacetate derivative. Biol. Mass Spectrom. 23, 440–444 (1994).
McLaurin, J. et al. Therapeutically effective antibodies against amyloid-beta peptide target amyloid-beta residues 4–10 and inhibit cytotoxicity and fibrillogenesis. Nat. Med. 8, 1263–1269 (2002).
Frenkel, D., Katz, O. & Solomon, B. Immunization against Alzheimer's β-amyloid plaques via EFRH phage administration. Proc. Natl. Acad. Sci. USA 97, 11455–11459 (2000).
Bard, F. et al. Epitope and isotype specificities of antibodies to β-amyloid peptide for protection against disease-like neuropathology. Proc. Natl. Acad. Sci. USA 100, 2023–2028 (2003).
Nicoll, J.A. et al. Neuropathology of human Alzheimer disease after immunization with amyloid-β peptide: a case report. Nat. Med. 9, 448–452 (2003).
Hock, C. et al. Antibodies against beta-amyloid slow cognitive decline in Alzheimer's disease. Neuron 38, 547–554 (2003).
Tanaka, M. et al. Trehalose alleviates polyglutamine-mediated pathology in a mouse model of Huntington disease. Nat. Med. 10, 148–154 (2004).
Lesne, S. et al. A specific amyloid-β protein assembly in the brain impairs memory. Nature 440, 352–357 (2006).
Fisher, S.K.,, Novak, J.E., & Agranoff, B.W. Inositol and higher inositol phosphates in neural tissues: homeostasis, metabolism and functional significance. J. Neurochem. 82, 736–754 (2002).
Vaucher, E. et al. Object recognition memory and cholinergic parameters in mice expressing human presenilin 1 transgenes. Exp. Neurol. 175, 398–406 (2002).
Mount, H.T. et al. Progressive sensorimotor impairment is not associated with reduced dopamine and high energy phosphate donors in a model of ataxia-telangiectasia. J. Neurochem. 88, 1449–1454 (2004).
Wiltfang, J. et al. Highly conserved and disease-specific patterns of carboxyterminally truncated Abeta peptides 1–37/38/39 in addition to 1–40/42 in Alzheimer's disease and in patients with chronic neuroinflammation. J. Neurochem. 81, 481–496 (2002).
Haccou, P. & Mellis, E. Statistical Analysis of Behavioural Data 120–186 (Oxford Univ Press, Oxford, 1995).
Chen, F. et al. Carboxyl-terminal fragments of Alzheimer beta-amyloid precursor protein accumulate in restricted and unpredicted intracellular compartments in presenilin 1-deficient cells. J. Biol. Chem. 275, 36794–36802 (2000).
Phinney, A. et al. No hippocampal neuron or synaptic bouton loss in learning-impaired aged β-amyloid precursor protein-null mice. Neuroscience 90, 1207–1216 (1999).
Hu, L. et al. The impact of Aβ-plaques on cortical cholinergic and non-cholinergic presynaptic boutons in Alzheimer's disease-like transgenic mice. Neuroscience 121, 421–432 (2003).
The authors thank C. Glabe for the oligomeric specific antibody, P. Mathews for the C1/6.1 antibody and R. Ahrens and P. Horne for technical assistance. The authors acknowledge support from the Ontario Alzheimer's Society (to H.T.J.M., P.H., P.E.F., D.W., J.M.), Canadian Institutes of Health Research (to H.T.J.M., P.H., P.E.F., D.W., J.M.), the Natural Sciences and Engineering Research Council of Canada (to J.M.), Canadian Foundation for Innovation (to H.T.J.M., P.H., P.E.F., D.W., J.M.), Ontario Research and Development Challenge Fund (to J.M., P.H., D.W., P.E.F.) Howard Hughes Medical Institute (to P.H.) and the Scottish Rite and Cryptic Foundations (to J.M.).
JoAnne McLaurin, Paul E. Fraser, David Westaway and Peter St. George-Hyslop and the University of Toronto have licensed this technology to a private-sector company from which support for a research program is derived.
JoAnne McLaurin is named as inventor on patent applications relating to this technology.
Cyclohexanehexol stereoisomer structures. (PDF 16 kb)
Spatial reference memory version of the Morris water maze test in 6-month-old TgCRND8 mice untreated and treated with mannitol. (PDF 98 kb)
At 6 months of age, the plaque burden and astrogliosis in TgCRND8 mice untreated, epi- and scyllo-cyclohexanehexoltreated mice were examined. (PDF 240 kb)
A cue test was performed at the end of the spatial memory version of the Morris water maze test. (PDF 25 kb)
In vitro γ-secretase assay in HEK293 cells trasfected with human PPswe. (PDF 143 kb)
Overall effect of cyclohexanehexols on cognitive function. (PDF 26 kb)
About this article
Cite this article
McLaurin, J., Kierstead, M., Brown, M. et al. Cyclohexanehexol inhibitors of Aβ aggregation prevent and reverse Alzheimer phenotype in a mouse model. Nat Med 12, 801–808 (2006). https://doi.org/10.1038/nm1423
Apolipoprotein E genotype-dependent nutrigenetic effects to prebiotic inulin for modulating systemic metabolism and neuroprotection in mice via gut-brain axis
Nutritional Neuroscience (2021)
Identification of a repressor for the two iol operons required for inositol catabolism in Geobacillus kaustophilus
The Journal of Physical Chemistry B (2021)
Frontiers in Neuroscience (2021)
ACS Medicinal Chemistry Letters (2021)